These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37175725)

  • 41. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
    Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
    J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of first-in-class thiazole-based dual FFA1/PPARĪ“ agonists as potential anti-diabetic agents.
    Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
    Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469.
    Urban C; Hamacher A; Partke HJ; Roden M; Schinner S; Christiansen E; Due-Hansen ME; Ulven T; Gohlke H; Kassack MU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1021-30. PubMed ID: 23861168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM
    J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.
    Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T
    Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel agonists of free fatty acid receptor 1 (GPR40) based on 3-(1,3,4-thiadiazol-2-yl)propanoic acid scaffold.
    Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1404-10. PubMed ID: 26899762
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.
    Lin DC; Guo Q; Luo J; Zhang J; Nguyen K; Chen M; Tran T; Dransfield PJ; Brown SP; Houze J; Vimolratana M; Jiao XY; Wang Y; Birdsall NJ; Swaminath G
    Mol Pharmacol; 2012 Nov; 82(5):843-59. PubMed ID: 22859723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
    Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
    Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists.
    Zhang X; Cai C; Winters M; Wells M; Wall M; Lanter J; Sui Z; Ma J; Novack A; Nashashibi I; Wang Y; Yan W; Suckow A; Hua H; Bell A; Haug P; Clapper W; Jenkinson C; Gunnet J; Leonard J; Murray WV
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3272-3278. PubMed ID: 28642104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy.
    Hansen SV; Christiansen E; Urban C; Hudson BD; Stocker CJ; Due-Hansen ME; Wargent ET; Shimpukade B; Almeida R; Ejsing CS; Cawthorne MA; Kassack MU; Milligan G; Ulven T
    J Med Chem; 2016 Mar; 59(6):2841-6. PubMed ID: 26928019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.
    Yang L; Zhang J; Si L; Han L; Zhang B; Ma H; Xing J; Zhao L; Zhou J; Zhang H
    Eur J Med Chem; 2016 Jun; 116():46-58. PubMed ID: 27054485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835.
    Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S; Ihalainen J; Forsberg MM; Lehtonen M; Rautio J; Moore D; Tikhonova IG
    Bioorg Med Chem; 2016 Nov; 24(21):5481-5494. PubMed ID: 27647366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
    Zhou Y; Wang Y; Zhang L; Tang C; Feng B
    Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
    Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
    Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bornyl Derivatives of
    Kuranov S; Luzina O; Khvostov M; Baev D; Kuznetsova D; Zhukova N; Vassiliev P; Kochetkov A; Tolstikova T; Salakhutdinov N
    Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33228030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators.
    Gajjar KA; Gajjar AK
    Curr Drug Discov Technol; 2020; 17(1):100-118. PubMed ID: 30160214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.